RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00037682.xml
PDF herunterladen
CC BY-NC-ND 4.0 · International Journal of Epilepsy 2025; 11(01): 004-012
DOI: 10.1055/s-0045-1802582
DOI: 10.1055/s-0045-1802582
Review Article
Antiseizure Medication in the Setting of Systemic Illness: A Focused Review
Abstract
Epilepsy is a common neurological disorder, and managing seizures can be challenging when other systemic illnesses are present, as these can affect the choice of antiseizure medication (ASM). Various comorbidities, such as cardiovascular disorders, liver and kidney impairment, psychiatric conditions, porphyria, and thyroid dysfunction, can significantly influence the pharmacokinetics and pharmacodynamics of ASMs. This requires careful selection of suitable ASMs based on their safety profiles and potential for drug interactions. Traditional ASMs such as phenytoin, carbamazepine, and valproate should be taken cautiously in individuals with cardiovascular disorders because of the possibility of side effects. Conversely, newer medications like lamotrigine and lacosamide (LCM) may offer safer alternatives. Levetiracetam and LCM are examples of medications with minimal hepatic metabolism, which are recommended since hepatic dysfunction can impact the binding potential of ASMs and result in toxicity. Furthermore, drugs that are mostly eliminated by the kidneys may take longer to be eliminated due to renal impairment, necessitating dose adjustments or the consideration of alternate therapies. ASMs can also affect psychiatric conditions; some medications may provide mood-stabilizing or antidepressant effects, while others may worsen psychiatric symptoms. Certain ASMs can trigger porphyria or disrupt thyroid function, necessitating careful monitoring and appropriate selection of treatments. This review offers a comprehensive overview of considerations and recommendations for the use of ASMs in various systemic illnesses, highlighting the need for a sophisticated strategy to maximize managing seizures while reducing side effects and medication interactions.
Keywords
epilepsy - antiseizure medications (ASMs) - systemic illnesses - pharmacokinetics - safety profilesPublikationsverlauf
Artikel online veröffentlicht:
12. Februar 2025
© 2025. Indian Epilepsy Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Beghi E, Giussani G, Nichols E. et al; GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (04) 357-375
- 2 Gunasekera CL, Sirven JI, Feyissa AM. The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?. J Cent Nerv Syst Dis 2023; 15: 11 795735231209209
- 3 Alsfouk BAA, Brodie MJ, Walters M. et al. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurol 2020; 77 (05) 574-581
- 4 Yamamoto Y, Terada K, Takahashi Y, Imai K, Kagawa Y, Inoue Y. Influence of antiepileptic drugs on serum lipid levels in adult epilepsy patients. Epilepsy Res 2016; 127: 101-106
- 5 Wyte CD, Berk WA. Severe oral phenytoin overdose does not cause cardiovascular morbidity. Ann Emerg Med 1991; 20 (05) 508-512
- 6 Wallis W, Kutt H, McDowell F. Intravenous diphenylhydantoin in treatment of acute repetitive seizures. 1968. Neurology 1998; 50 (06) 1525-1525 , 13
- 7 Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991; 20 (02) 139-142
- 8 Marchetti A, Magar R, Fischer J, Sloan E, Fischer P. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther 1996; 18 (05) 953-966
- 9 Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia 2010; 51 (05) 725-737
- 10 Takayanagi K, Yamaguchi H, Hayashi T, Morooka S, Takabatake Y. Carbamazepine-induced bradycardia-tachycardia syndrome with pharmacological analysis and concurrent ECG monitoring. J Electrocardiol 1990; 23 (01) 85-88
- 11 Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992; 152 (01) 186-191
- 12 Jia L, Eroglu TE, Wilders R, Verkerk AO, Tan HL. Carbamazepine increases the risk of sudden cardiac arrest by a reduction of the cardiac sodium current. Front Cell Dev Biol 2022; 10: 891996
- 13 Gilad R, Izkovitz N, Dabby R. et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008; 118 (05) 296-300
- 14 Radgoudarzi M, Vafaee-Shahi M, Naderi F. Effect of sodium valproate treatment on the cardiac index in new cases with status epilepticus. Open Neurol J 2021; 15: 59-64
- 15 Nagendra K, Wilson C, Ravichander B, Sood S, Singh S. Incidence and etiology of respiratory distress in newborn. Med J Armed Forces India 1999; 55: 331-333
- 16 Lu Y-T, Lin C-H, Ho C-J, Hsu C-W, Tsai M-H. Evaluation of cardiovascular concerns of intravenous lacosamide therapy in epilepsy patients. Front Neurol 2022; 13: 891368
- 17 French JA, Perucca E, Sander JW. et al. FDA safety warning on the cardiac effects of lamotrigine: an advisory from the Ad Hoc ILAE/AES Task Force. Epilepsy Curr 2021; 21 (03) 15 35759721996344
- 18 Restrepo JA, MacLean R, Celano CM, Huffman JC, Januzzi JL, Beach SR. The assessment of cardiac risk in patients taking lamotrigine; a systematic review. Gen Hosp Psychiatry 2022; 78: 14-27
- 19 Christensen J, Trabjerg BB, Dreier JW. Cardiac morbidity and mortality associated with the use of lamotrigine. Epilepsia 2022; 63 (09) 2371-2380
- 20 Eslicarbazine acetate (Aptiom). Accessed January 25, 2024 at: https://www.aptiom.com/
- 21 Cenobamate (Xcopri). Accessed January 19, 2025 at: https://reference.medscape.com/drug/ xcopricenobamate- 1000328/ 2020
- 22 Rufinamide (Banzel). Accessed January 25, 2024 at: https://www.banzel.com/
- 23 Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet 2014; 53 (01) 29-49
- 24 Ruiz-Giménez J, Sánchez-Alvarez JC, Cañadillas-Hidalgo F, Serrano-Castro PJ. Andalusian Epilepsy Society. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 2010; 19 (07) 375-382
- 25 Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol 2014; 119: 417-432
- 26 Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005; 77 (06) 529-541
- 27 Romigi A, Placidi F, Liguori C. et al. Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. Epilepsy Behav Case Rep 2014; 2: 161-163
- 28 Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15 (03) 156-164
- 29 Ahn S, Hong Y-H, Lee DH. et al. Efficacy and safety of pregabalin for muscle cramps in liver cirrhosis: a double-blind randomized controlled trial. J Korean Med Sci 2022; 37 (07) e56
- 30 Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol 2017; 77: 23-36
- 31 Brivaracetam (Briviact). Accessed January 25, 2024 at: https://www.briviact.com/
- 32 Cannabidiol (Epidiolex). Accessed January 25, 2024 at: https://www.epidiolex.com/
- 33 Diaz A, Deliz B, Benbadis SR. The use of newer antiepileptic drugs in patients with renal failure. Expert Rev Neurother 2012; 12 (01) 99-105
- 34 Dogukan A, Aygen B, Berilgen MS, Dag S, Bektas S, Gunal AI. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006; 10: 168-169
- 35 Vulliemoz S, Iwanowski P, Landis T, Jallon P. Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. Seizure 2009; 18 (05) 376-378
- 36 Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial 2015; 28 (04) 404-412
- 37 Mahmoud SH. Antiepileptic drug removal by continuous renal replacement therapy: a review of the literature. Clin Drug Investig 2017; 37 (01) 7-23
- 38 Kawai M, Goji H, Kanemoto K. Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy. Epilepsy Behav 2022; 126: 108493
- 39 Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62 (04) 345-354
- 40 Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999; 13 (04) 317-356
- 41 Trimble MR, Mula M. Antiepileptic drug interactions in patients requiring psychiatric drug treatment. In: Antiepileptic Drugs. Cambridge University Press; 2005: 350-368
- 42 Busko M. FDA advisory members agree antiepileptics pose suicidality risk, nix need for black-box warning. [Internet]. Medscape; 2008. Accessed October 21, 2023 at: medscape.com/viewarticle/577432
- 43 Hesdorffer DC, Berg AT, Kanner AM. An update on antiepileptic drugs and suicide: are there definitive answers yet?. Epilepsy Curr 2010; 10 (06) 137-145
- 44 Wang H, Zhang Y, Tan G, Chen D, Fu Y, Liu L. Suicidality and epilepsy: a systematic review and meta-analysis. Front Psychiatry 2023; 14: 1097516
- 45 Harden CL. Sexuality in men and women with epilepsy. CNS Spectr 2006; 11 (8, suppl 9): 13-18
- 46 Facts and Comparisons. Drug Facts and Comparisons. St. Louis: Wolters Kluwer Health/ Facts and Comparisons; 2007
- 47 Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr 2005; 5 (05) 176-181
- 48 Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67 (12, suppl 4): S39-S44
- 49 Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol 2005; 32 (01) 1-10
- 50 Smith MC. Optimizing therapy of seizures in children and adolescents with developmental disabilities. Neurology 2006; 67 (12, suppl 4): S52-S55
- 51 Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27 (03) 263-272
- 52 Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29 (01) 26-48
- 53 Kaufman KR. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav 2011; 21 (01) 1-11
- 54 Bialer M. Why are antiepileptic drugs used for nonepileptic conditions?. Epilepsia 2012; 53 (Suppl. 07) 26-33
- 55 Kimiskidis VK, Valeta T. Epilepsy and anxiety: epidemiology, classification, aetiology, and treatment. Epileptic Disord 2012; 14 (03) 248-256
- 56 Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol 2016; 12 (02) 106-116
- 57 Solinas C, Vajda FJ. Epilepsy and porphyria: new perspectives. J Clin Neurosci 2004; 11 (04) 356-361
- 58 Hahn M, Gildemeister OS, Krauss GL. et al. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997; 49 (01) 97-106
- 59 Tatum IV WOIV, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45 (06) 1216-1217
- 60 Gaida-Hommernick B, Rieck K, Runge U. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001; 42 (06) 793-795
- 61 Taylor RL. Magnesium sulfate for AIP seizures. Neurology 1981; 31 (10) 1371-1372
- 62 Weir PM, Hodkinson BP. Is propofol a safe agent in porphyria?. Anaesthesia 1988; 43 (12) 1022-1023
- 63 Elshorbagy HH, Barseem NF, Suliman HA. et al. the impact of antiepileptic drugs on thyroid function in children with epilepsy: new versus old. Iran J Child Neurol 2020; 14 (01) 31-41
- 64 Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol 2015; 8 (06) 741-750
- 65 Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet 2015; 385 (9971): 884-898
- 66 Shih F-Y, Chuang Y-C, Chuang M-J. et al. Effects of antiepileptic drugs on thyroid hormone function in epilepsy patients. Seizure 2017; 48: 7-10
- 67 Adhimoolam M, Arulmozhi R. Effect of antiepileptic drug therapy on thyroid hormones among adult epileptic patients: an analytical cross-sectional study. J Res Pharm Pract 2016; 5 (03) 171-174